Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Am J Transplant. 2015 Apr 30;15(8):2223–2230. doi: 10.1111/ajt.13281

Figure 1.

Figure 1

Flowchart describing the number of patients that were excluded because they were re-transplanted for another cause than CLAD resulting in 143 re-LTx. From these 143, 94 were suffering from BOS and 49 from rCLAD. After re-LTx, 40 patients re-developed CLAD of which 25 developed BOS and 13 rCLAD.

HHS Vulnerability Disclosure